Anti-Inhibitor Coagulant Complex has 8 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Aminocaproic Acid, Emicizumab, Fitusiran. Patients taking Anti-Inhibitor Coagulant Complex should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 8
- Major
- 4
- Moderate
- 3
Major (4)
- Anti-Inhibitor Coagulant Complex + Aminocaproic Acid— Systemic antifibrinolytic; increased risk of thrombotic events. Use not recommended within 6-12 hours after FEIBA admini…
- Anti-Inhibitor Coagulant Complex + Emicizumab— Clinical experience suggests potential drug interaction exists when FEIBA is used for breakthrough bleeding treatment du…
- Anti-Inhibitor Coagulant Complex + Fitusiran— Concomitant use leads to increased thrombin generation with additive increase in peak thrombin, resulting in hypercoagul…
- Anti-Inhibitor Coagulant Complex + Tranexamic Acid— Not recommended due to increased risk of thrombosis when used concomitantly with tranexamic acid.
Moderate (3)
- Anti-Inhibitor Coagulant Complex + Ciprofloxacin— Increase in anticoagulant effect with risk of elevated INR. Monitor prothrombin time and INR frequently during and after…
- Anti-Inhibitor Coagulant Complex + Darunavir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide— Co-administration may result in increased plasma concentrations of darunavir and cobicistat.
- Anti-Inhibitor Coagulant Complex + Norethindrone— May significantly change plasma levels of norethindrone, affecting safety and efficacy of contraceptive. Individual prot…